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Background. Clostridium difficile–associated diarrhea (CDAD) is common during hematopoietic stem-cell transplantation
(HSCT) and is associated with increased morbidity and mortality. We evaluated fidaxomicin for prevention of CDAD in HSCT patients.
Methods. In this double-blind study, subjects undergoing HSCT with fluoroquinolone prophylaxis stratified by transplant type
(autologous/allogeneic) were randomized to once-daily oral fidaxomicin (200 mg) or a matching placebo. Dosing began within
2 days of starting conditioning or fluoroquinolone prophylaxis and continued until 7 days after neutrophil engraftment or completion of fluoroquinolone prophylaxis/clinically-indicated antimicrobials for up to 40 days. The primary endpoint was CDAD incidence through 30 days after study medication. The primary endpoint analysis counted confirmed CDAD, receipt of CDAD-effective
medications (for any indication), and missing CDAD assessment (for any reason, including death) as failures; this composite analysis
is referred to as “prophylaxis failure” to distinguish from the pre-specified sensitivity analysis, which counted only confirmed CDAD
(by toxin immunoassay or nucleic acid amplification test) as failure.
Results. Of 611 subjects enrolled, 600 were treated and analyzed. Prophylaxis failure was similar in fidaxomicin and placebo
recipients (28.6% vs 30.8%; difference 2.2% [-5.1, 9.5], P = .278). However, most failures were due to non-CDAD events. Confirmed
CDAD was lower in fidaxomicin vs placebo recipients (4.3% vs 10.7%; difference 6.4% [2.2, 10.6], P = .0014). Drug-related adverse
events occurred in 15.0% of fidaxomicin recipients and 20.0% of placebo recipients.
Conclusions. While no difference was demonstrated between arms in the primary analysis, results of the sensitivity analysis
demonstrated that fidaxomicin significantly reduced the incidence of CDAD in HSCT recipients.
Clinical Trials Registration. NCT01691248
Keywords. fidaxomicin; hematopoietic stem-cell transplantation; Clostridium difficile–associated diarrhea; prophylaxis.
The incidence of Clostridium difficile–associated diarrhea
(CDAD) among recipients of hematopoietic stem cell transplantation (HSCT) is 5- to 9-fold higher compared to the general
hospitalized population [1–3]. Contributing risk factors include
cytotoxic chemotherapy, broad-spectrum antibiotics, and, possibly, graft-versus-host disease (GVHD) [4–7]. Rates of confirmed
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CDAD range from 5–15% in autologous HSCT (auto-HSCT)
recipients [8] and from 12–34% in allogeneic HSCT (alloHSCT) recipients [7, 9, 10]. CDAD after allo-HSCT has been
associated with higher rates of new-onset GVHD, blood stream
infections, and non-relapse mortality [4, 6, 11, 12].
Fidaxomicin at 200 mg orally twice daily is approved for
the treatment of CDAD in adults, and is recommended as initial therapy for new-onset CDAD [13]. Fidaxomicin is a narrow-spectrum, macrolide antibiotic that is bactericidal against
C. difficile in vitro [14–17], strongly inhibits the production
of C. difficile toxins A and B [18], and has minimal effects on
the gut microbiota [19]. Fidaxomicin and its major metabolite
(OP-1118) are potent inhibitors of C. difficile spore formation
[20]. In 2 randomized, controlled trials [21, 22], fidaxomicin
at 200 mg twice daily was non-inferior to oral vancomycin
at 125 mg 4 times daily in achieving clinical cures of CDAD,
and resulted in significantly lower rates of CDAD recurrence
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A Randomized, Placebo-controlled Trial of Fidaxomicin
for Prophylaxis of Clostridium difficile–associated
Diarrhea in Adults Undergoing Hematopoietic Stem Cell
Transplantation

METHODS
Study Design and Participants

DEFLECT-1 (Protocol OPT-80-302; ClinicalTrials.gov
NCT01691248) was a randomized, double-blind, placebo-controlled study conducted at 42 centers in North America and
approved by the Ethical Review Committee at each study site.
Individuals ≥18 years of age undergoing HSCT—including those
receiving reduced-intensity (T-cell depleted) conditioning and
“mini-transplants”—with planned fluoroquinolone prophylaxis
during neutropenia were eligible for the study. Fluoroquinolone
prophylaxis was chosen in order to standardize prophylaxis for
bacterial infections, per the American Society of Blood and
Bone Marrow Transplantation Guidelines [25]. Exclusion criteria included active CDAD infection (confirmed by toxin immunoassay or nucleic acid amplification tests [NAAT]) or ongoing
treatment for CDAD; fulminant colitis, toxic megacolon, or
ileus; receipt of a cord blood transplant; history of inflammatory bowel disease; pregnancy or breast-feeding; and current
use of any drugs potentially useful in the treatment of CDAD
(eg, oral vancomycin, metronidazole, oral bacitracin, fusidic
acid, rifaximin, nitazoxanide). Study participants provided
written informed consent before any study-related procedures
were performed.

drug was continued until 7 days after neutrophil engraftment
(absolute neutrophil count [ANC] ≥ 500 cells/mm3 for 3 consecutive days or white blood cell count [WBC] >1000 cells/
mm3 for 2 consecutive days); the completion of fluoroquinolone prophylaxis or any other systemic concomitant antibiotic
therapy required for empiric management of febrile neutropenia or treatment of a concurrent infection during the study,
whichever occurred later; or until the onset of confirmed
CDAD (Supplementary Figure 1). Treatment duration was not
to exceed 40 days, regardless of the time of engraftment or cessation of any antibacterial therapy. No other drugs potentially
useful in the treatment of CDAD (eg, oral vancomycin, metronidazole) were allowed during the trial. Subjects requiring
these medications for any reason were discontinued from study
treatment.
Subjects were managed per institutional guidelines. Subjects
were evaluated for CDAD symptoms twice weekly during study
drug treatment, followed by twice-weekly telephone contacts
through 30 days and then weekly telephone contacts through
60 days post-treatment. If CDAD was suspected, a stool sample was assayed for the presence of C. difficile based on the
standard of care at the study site (either toxin immunoassay or
NAAT). Subjects with confirmed CDAD during the treatment
period or during the follow-up period were placed on standard
of care treatment per local guidelines for CDAD management.
Subjects were followed through 30 days post-treatment for
all adverse events (AEs) and through 60 days post-treatment
for serious AEs. Safety was assessed through laboratory evaluations (hematology, biochemistry, and urinalysis), vital signs
(blood pressure, heart rate, and temperature), and physical
examinations.
Statistical Analysis

Primary Efficacy Endpoint

The primary efficacy outcome was the incidence of CDAD
from the first dose of study drug through 30 days after the last
dose of study drug. Confirmed CDAD was defined as diarrhea
(>3 unformed bowel movements in 24 hours) and a positive test
for the presence of C. difficile (either by toxin immunoassay or
NAAT).

Procedures

Secondary Efficacy Endpoints

Subjects were stratified by transplant type (autologous
vs allogeneic stem cells) and randomly assigned (1:1) to
receive oral fidaxomicin (200 mg) or a matching placebo
once daily. Based on fecal concentration data from subjects without CDAD [26] and patients with mild to moderate CDAD [27], the fidaxomicin dose of 200 mg/day was
considered likely to achieve fecal concentrations capable of
suppressing C. difficile growth.
Dosing began within 2 days of start of conditioning or at
fluoroquinolone initiation, whichever occurred first. The study

CDAD incidence was also evaluated at 2 secondary time points:
through 60 days after the last dose of the study drug, and
through 70 days after the first dose of the study drug. Time to
onset of CDAD was an exploratory outcome.
Safety outcomes included treatment-emergent AEs, all-cause
mortality, gastrointestinal hemorrhagic events, time to neutrophil engraftment (time elapsed from date of neutropenia
[ANC < 500 cells/mm3] to the first of 3 consecutive days with
ANC ≥500 cells/mm3 or the first of 2 consecutive days with
WBC ≥1000 cells/mm3), and acute GVHD.
Prophylaxis of CDAD in HSCT Patients • CID 2019:68 (15 January) • 197
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(13–15% vs 25–27%). In a post hoc analysis of combined data
from these 2 trials, fidaxomicin was significantly more effective
than vancomycin in achieving clinical cures in the presence of
concomitant antibiotic therapy and in preventing recurrence,
regardless of concomitant antibiotic use [23]. Another post
hoc analysis of these 2 trials showed that cancer patients who
received fidaxomicin had significantly higher rates of clinical
cures and sustained clinical responses than cancer patients who
received vancomycin [24].
Given the increased risk for CDAD and its associated complications, prevention of CDAD may be of benefit in HSCT
patients. This study examined the efficacy and safety of fidaxomicin as a prophylaxis against CDAD in patients undergoing
allo- or auto-HSCT and receiving fluoroquinolone prophylaxis
during neutropenia.

Primary and Sensitivity Analyses, Taking into Account Missing
Efficacy Variables

The primary analysis classified the following outcomes as
prophylaxis failure: (1) confirmed CDAD, (2) use of antibiotics potentially effective against CDAD (eg, metronidazole) for
any reason, including suspected CDAD or non-CDAD indications (because CDAD-effective antibiotics would confound the
CDAD assessment), and (3) missing CDAD assessments (clinical evaluation and/or toxin or NAAT assay) due to death or
AE, or for any other reason (eg, loss to follow-up, missed study
visits). This composite analysis was chosen as a conservative
approach for handling missing data in a Phase 3 registration
trial. However, because there are many reasons for missing data
that are unrelated to C. difficile (eg, mortality due to underlying
cancer), a pre-specified sensitivity analysis restricted to confirmed CDAD only (ie, those cases confirmed by a toxin test or
NAAT) was planned a priori in order to evaluate the incidence
of CDAD independent of missing data (see Supplementary
Materials Protocol Section 11.9).
A 1-sided Wald test for a difference in proportions using an
unpooled estimate of variance was used to test for superiority
of fidaxomicin compared to the placebo at 1-sided α = .025.
A 95% confidence interval surrounding the point estimate of
the difference was calculated based on the stage-wise ordering
method of Tsiatis [28]. Time to onset of confirmed CDAD and
time to neutrophil engraftment were analyzed by the KaplanMeier survival analysis method [29]. The survival curves for
fidaxomicin and placebo were compared using the generalized
Wilcoxon and log-rank tests.
In a post hoc analysis, baseline stool samples were assayed
centrally by NAAT (Cepheid Xpert C. difficile/Epi) to determine the relationship between baseline C. difficile colonization
and the occurrence of confirmed CDAD, analyzed via chisquare testing.
RESULTS

Of the 611 subjects enrolled and allocated to treatment, 600
received at least 1 dose of a study drug and were assessed for
safety and efficacy (Figure 1). Study treatment was completed
by 227 (75.4%) fidaxomicin recipients and 218 (72.9%) placebo
recipients. The mean (±SD) duration of treatment was 22.0
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(±8.61) days in the fidaxomicin group and 22.7 (±8.99) days in
the placebo group. Approximately 64% of subjects in each treatment group completed study treatment and follow-up. While all
subjects were required to receive prophylactic fluoroquinolone
antibiotics for eligibility, 75% also received non-fluoroquinolone (and non–CDAD effective) systemic antibiotics, primarily
cephalosporins (56.2%), intravenous vancomycin (52.2%), and
carbapenems (18.8%), during study treatment or follow-up.
Demographic and baseline characteristics were balanced
across treatment groups (Table 1). Most subjects (79.2%) were
inpatients at study entry, and a majority (58.7%) received autoHSCT. For the allo-HSCT recipients, most donors were either
human leukocyte antigen–matched unrelated donors or siblings (Table 1). Myeloablative conditioning regimens were more
common than non-myeloablative regimens. Reasons for HSCT
were diverse, comprising 64 distinct syndromes; the most common were multiple myeloma, acute myeloid leukemia, myelodysplastic syndrome, Hodgkin’s disease, and diffuse large B-cell
lymphoma.
Primary Efficacy Endpoint, Taking into Account Missing Efficacy Variables

For the primary analysis, prophylaxis failure through 30 days
post-treatment occurred in 28.6% of fidaxomicin-treated
patients and 30.8% of those receiving the placebo (P = .278). The
majority of failures in this composite analysis were attributed
to non–CDAD related events: specifically, receipt of antibiotics potentially effective against CDAD (metronidazole in most
cases), missing a CDAD assessment due to death or to study
discontinuation due to an AE, and missing a CDAD assessment
for any other reason (Table 2). Prophylaxis failure through later
time points was not significantly different between fidaxomicin
and the placebo (Table 2).
Sensitivity Analysis

In the sensitivity analysis, the incidence of confirmed CDAD
through 30 days post-treatment was significantly lower in
fidaxomicin recipients compared with placebo recipients (4.3
vs 10.7%, respectively; P = .0014). Similarly, the incidence of
confirmed CDAD was lower in the fidaxomicin group than in
the placebo group through 60 days after study treatment ended
(5.6 vs 10.7%, respectively; P = .0117) and through study day
70 (4.7 vs 10.7%, respectively; P = .0026). Confirmed CDAD
was more common in allo-HSCT recipients than in auto-HSCT
recipients in both treatment groups, and was reduced in the
fidaxomicin group compared with the placebo group for both
transplant types (Table 2).
Secondary Analyses

When baseline stool samples were analyzed retrospectively for
colonization using NAAT, 47/456 (10.3%) were positive for colonization at baseline. Of the 47 that were colonized, 16 (35.6%)
later developed confirmed CDAD; 5 (31.2%) were treated with
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Efficacy analyses used the modified Intent-to-treat (mITT)
Analysis Set, defined as all randomized subjects undergoing
HSCT who received ≥1 dose of a study drug, with subjects
included in the treatment group to which they were randomized. The Safety Analysis Set included all randomized subjects
who received ≥1 dose of a study drug and had ≥1 post-dose
safety assessment, with subjects grouped by the treatment actually received. SAS version 9.3 (SAS Institute Inc., Cary, NC) was
used for all statistical analyses.

N = 611
All Randomized

N = 305
Fidaxomicin 200 mg

N = 306
Placebo

N = 301

N = 299
Received HSCT

N = 301
mITT Analysis Set

N = 107 Withdrawn
• Protocol noncompliance (43)
• Adverse event (24)
• Subject decision (20)
• Confirmed CDAD (14)
• Lost to follow-up (2)
• Other (4)

N = 300
Safety Analysis Set

N = 194
Completed

N = 299
mITT Analysis Set

N = 192
Completed

Had at least
1 safety assessment

N = 107 Withdrawn
• Protocol noncompliance (27)
• Adverse event (22)
• Subject decision (18)
• Confirmed CDAD (31)
• Lost to follow-up (5)
• Other (4)

N = 300
Safety Analysis Set

Figure 1. Trial profile. “Completed” refers to when a subject completed all study visits without prophylaxis failure or missing data for any of the reasons listed. Placebo
was administered in error to 1 subject randomized to fidaxomicin. Abbreviations: CDAD, Clostridium difficile–associated diarrhea; HSCT, hematopoietic stem cell transplant;
mITT, modified intent-to-treat.

fidaxomicin and 11 with placebo (68.8%). Of the 409 subjects
not colonized at baseline, only 16 (3.9%) developed confirmed
CDAD: 7 (44%) in the fidaxomicin arm and 9 (56%) in the placebo arm. Thus, later development of CDAD was more likely
in subjects with C. difficile colonization at baseline (P < .0001;
Supplementary Table 1).
The incidence of CDAD over time diverged significantly
between the treatment groups (Figure 2). In the placebo group,
most events occurred within the first 2–3 weeks after study
start, while in the fidaxomicin group there was a trend towards
later occurrence.
While both toxin (enzyme-linked immunosorbent assay
[ELISA]) and toxin gene (NAAT) tests were allowed for confirmation of C. difficile, most sites in this study used direct toxin
detection. Of the 45 confirmed cases of CDAD through 30 days
post-treatment, 29 were confirmed directly by toxin test and 9
were confirmed by NAAT; for the remaining 7 cases, the test
method was undefined.
At least 1 treatment-emergent AE was reported by nearly all
subjects in both treatment groups (Supplementary Table 2).

The most frequently reported AEs were diarrhea (fidaxomicin 71.0%, placebo 73.3%), nausea (fidaxomicin 62.3%, placebo 67.0%), febrile neutropenia (fidaxomicin 48.0%, placebo
37.0%), and vomiting (fidaxomicin 41.0%, placebo 41.0%). AEs
were considered by the investigator to be at least possibly related
to the study drug in 15.0% of the fidaxomicin group and 20.0%
of the placebo group. Most drug-related AEs were of similar or
lower frequency in the fidaxomicin group versus the placebo
group (Supplementary Table 2).
Serious AEs were reported for nearly one-third of subjects
(fidaxomicin 32.7%, placebo 30.7%), and were considered
drug-related in 1.3% of fidaxomicin and 0.7% of placebo recipients. A total of 27 subjects died during the study: 13 (4.3%) in
the fidaxomicin group and 14 (4.7%) in the placebo group. None
of the deaths were considered drug-related or were attributed to
C. difficile (Supplementary Table 3), and only 3 had developed
confirmed CDAD. All-cause mortality was not significantly different between treatment groups (Pearson’s chi-square test).
The median time to neutrophil engraftment was 9 days
(interquartile range [IQR], 7–13 days) in the fidaxomicin
Prophylaxis of CDAD in HSCT Patients • CID 2019:68 (15 January) • 199

Downloaded from https://academic.oup.com/cid/article/68/2/196/5035214 by Washington University, Law School Library user on 14 September 2020

Received at least
1 dose study drug

Table 1.

Baseline Characteristics (Modified Intent-to-treat Population)
Fidaxomicin (N = 301)

Placebo (N = 299)

Total (N = 600)

55.1 (12.00)

55.1 (13.23)

55.1 (12.62)

Male

176 (58.5)

196 (65.6)

372 (62.0)

Female

125 (41.5)

103 (34.4)

228 (38.0)

Age (years), mean (SD)
Sex, n (%)

Randomization stratum, n (%)
176 (58.5)

176 (58.9)

352 (58.7)

125 (41.5)

123 (41.1)

248 (41.3)

  HLA-matched sibling

50 (16.6)

40 (13.4)

90 (15.0)

   HLA-matched unrelated donor

62 (20.6)

68 (22.7)

130 (21.7)

  HLA mismatched

8 (2.7)

7 (2.3)

15 (2.5)

  Haploidentical

5 (1.7)

8 (2.7)

13 (2.2)

241 (80.1)

234 (78.3)

475 (79.2)

60 (19.9)

65 (21.7)

125 (20.8)

Hospitalization status at study entry, n (%)
Inpatient
Outpatient
Baseline renal Disease (CRCL), n (%)
Normal (≥90 mL/min/1.73 m2)

228 (75.7)

214 (71.6)

442 (73.7)

Stage 1 (60–89 mL/min/1.73 m2)

53 (17.6)

60 (20.1)

113 (18.8)

Stage 2 (30–59 mL/min/1.73 m2)

13 (4.3)

15 (5.0)

28 (4.7)

225 (74.8)

236 (78.9)

461 (76.8)

75 (24.9)

61 (20.4)

136 (22.7)

1 (0.3)

2 (0.7)

3 (0.5)

Type of conditioning, n (%)
Ablative
Non-myeloablative
Botha
Most common reasons for transplant (≥2% incidence)
Multiple myeloma

96 (31.9)

92 (30.8)

Acute myeloid leukaemia

39 (13.0)

43 (14.4)

188 (31.3)
82 (13.7)

Diffuse large B-cell lymphoma

19 (6.3)

12 (4.0)

31 (5.2)
36 (6.0)

Myelodysplastic syndrome

18 (6.0)

18 (6.0)

Acute lymphocytic leukaemia

12 (4.0)

7 (2.3)

19 (3.2)

B-cell lymphoma

12 (4.0)

4 (1.3)

16 (2.7)

Non-Hodgkin’s lymphoma

12 (4.0)

10 (3.3)

22 (3.7)

Hodgkin’s disease

11 (3.7)

21 (7.0)

32 (5.3)

Myeloid leukaemia

7 (2.3)

6 (2.0)

13 (2.2)

Mantle cell lymphoma

6 (2.0)

13 (4.3)

19 (3.2)

Abbreviations: CRCL, creatinine clearance; HLA, human leukocyte antigen.
a

Patients received tandem (sequential) autologous transplantation.

group and 9 days (IQR, 7–12 days) in the placebo group
(Supplementary Figure 2). Gastrointestinal hemorrhagic
events occurred in 2.7% (8/300) of fidaxomicin recipients
and 5.0% (15/300) of placebo recipients (P = .1366). In subjects undergoing allo-HSCT, acute GVHD occurred in 39.5%
(49/124) and 41.9% (52/124) of the fidaxomicin and placebo
groups, respectively (P = .6982).
DISCUSSION

Patients undergoing HSCT are at increased risk for CDAD for
a variety of reasons, including chemotherapy-induced immunosuppression, mucosal barrier injuries, antimicrobial prophylaxis, and antibiotic therapy given empirically or for documented
infections. This study evaluated fidaxomicin 200 mg once daily
as a CDAD prophylaxis in subjects undergoing allo- or autoHSCT and receiving fluoroquinolone antibiotics, followed to
60 days post-transplant. The rate of prophylactic failure based
on a composite analysis was not significantly different between
200 • CID 2019:68 (15 January) • Mullane et al

fidaxomicin and placebo. This lack of a difference between
fidaxomicin and placebo was primarily due to non-CDAD
events. In contrast, a pre-specified sensitivity analysis showed a
significantly lower rate of confirmed CDAD at 30 and 60 days in
those who received fidaxomicin prophylaxis. Fidaxomicin was
generally tolerated well and did not affect all-cause mortality,
time to neutrophil engraftment, or incidence of gastrointestinal
hemorrhage or GVHD. The overall safety profile of fidaxomicin
was similar to that of placebo.
In our study population, 58.7% of subjects received autoHSCT and 41.3% received allo-HSCT. For both transplant types,
the incidence of confirmed CDAD was lower in the fidaxomicin group than in the placebo group at 30 days post-treatment
(6.4 vs 14.6% after allo-HSCT; 2.8 vs 8.0% after auto-HSCT).
CDAD incidence among subjects who received placebo (ie, no
prophylaxis) was in the lower range of previously-reported rates
for CDAD in allo-HSCT patients (12–34%) and auto-HSCT
patients (5–15%) [7, 9, 10].
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Autologous transplant
Allogeneic transplant

Table 2.

Efficacy Analyses (Modified Intent-to-treat Population)
Fidaxomicin (N = 301)

Placebo (N = 299)

Placebo − FDX (95% CI)a

P-valueb

.2778

Primary analysis: prophylaxis failure (composite endpoint), n (%)
Primary time point
30 days after end of treatment

86 (28.6)

92 (30.8)

2.2 (-5.1, 9.5)

Confirmed CDAD

13 (4.3)

32 (10.7)

6.4 (2.2, 10.6)

.0014

CDAD-effective medicationc

12 (4.0)

11 (3.7)

-0.3 (-3.4, 2.8)

.4222

19 (6.3)

16 (5.4)

-1.0 (-4.7, 2.8)

.3077

Missing data (other reasond)

42 (14.0)

33 (11.0)

-3.0 (-8.2, 2.4)

.1397

60 days after end of treatment

106 (35.2)

107 (35.8)

0.6 (-7.1, 8.2)

.4420

70 days after start of treatment

88 (29.2)

93 (31.1)

1.9 (-5.5, 9.2)

.3091

32 (10.7)

Secondary time points

Sensitivity analysis: confirmed CDAD only, n (%)
Primary time point
30 days after end of treatment

6.4 (2.2, 10.6)

.0014

Autologous transplant

5/176 (2.8)

13 (4.3)

14/176 (8.0)

5.1 (0.4, 9.8)

.0163

Allogeneic transplant

8/125 (6.4)

18/123 (14.6)

8.2 (0.7, 15.8)

.0166

Secondary time points
60 days after end of treatment

5.1 (0.7, 9.4)

.0117

Autologous transplant

6/176 (3.4)

14/176 (8.0)

4.5 (-0.3, 9.4)

.0321

Allogeneic transplant

11/125 (8.8)

18/123 (14.6)

5.8 (-2.1, 13.8)

.0759

14 (4.7)

32 (10.7)

6.1 (1.8, 10.3)

.0026

70 days after start of treatment

17 (5.6)

32 (10.7)

Abbreviations: AE, adverse event; CDAD, Clostridium difficile–associated diarrhea; CI, confidence interval; FDX, fidaxomicin.
a

2-sided Wald 95% CI surrounding the difference in CDAD incidence.

b

1-sided Wald statistics.

c

Vancomycin was taken by 1 subject in the fidaxomicin group, for suspected C. difficile infection. Metronidazole was taken by 11 subjects in each treatment group; indications for use were
diarrhea (3), fever (3), non–C. difficile infection (3), bacterial infection (2), colitis (2), rectal abscess (2), enteritis/abdominal pain (1), diverticulitis (1), immunocompromised host prophylaxis (1),
gangrenous cholecystitis/tachycardia (1), suspected intestinal infection (1), catheter infection (1), and septic shock (1).
d

Subject was lost to follow-up, withdrew from study, or missed a study visit.

HSCT recipients, especially allo-HSCT recipients, are a complex group, with both infectious and non-infectious factors contributing to morbidity and mortality. In this trial, 4% of patients
received metronidazole for non-CDAD indications and were
considered prophylaxis failures. Other factors contributing to
prophylaxis failure were missing CDAD assessments due to
death or discontinuation from the study based on AEs (6%) or
for other reasons (12.5%) such as missed study visits, loss to
follow-up, or withdrawal of consent. The imputation of these

missing data as CDAD may account, in part, for the lack of significant difference in this analysis. When the more definitive
and clinically-relevant endpoint of confirmed CDAD was used
in the sensitivity analysis, a significant benefit for reduction of
CDAD by fidaxomicin was identified.
There are no guidelines for use of antimicrobial agents to
prevent CDAD in HSCT recipients, nor has this been previously studied in a large, double-blind, placebo-controlled
trial. However, 2 single-center retrospective cohort studies of

Figure 2. Time to onset of confirmed CDAD (modified intent-to-treat population). CDAD, Clostridium difficile–associated diarrhea; CI, confidence interval; HR, hazard ratio.
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The unmet medical need for a mechanism to prevent CDAD in
HSCT recipients prompted this clinical investigation.
Based on the results of this study, prophylaxis of CDAD with
fidaxomicin can reduce the incidence of confirmed CDAD
in the HSCT population. Patients with a history of CDAD or
C. difficile colonization prior to transplantation or who are at
risk for recurrent CDAD after transplantation, especially, may
be suitable candidates for fidaxomicin prophylaxis. Further
prophylactic studies designed around these specific high-risk
patients are needed.
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vancomycin prophylaxis in allo-HSCT were recently presented
[30, 31]. The first study examined CDAD incidence during
inpatient admission among 105 consecutive allo-HSCT recipients; CDAD occurred in 0/50 patients who received prophylaxis
with oral vancomycin (125 mg twice daily from admission until
discharge) compared to 11/55 (20%) patients who received no
prophylaxis (P < .001) [30]. No follow-up to evaluate occurrence of CDAD after discharge was reported. The second study
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infection (CDI), CDAD occurred in 2/12 (16.6%) who received
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history of CDI and did not receive prophylactic vancomycin;
CDAD occurred in 17 (10.6%) of this cohort [31].
A potential limitation of this study is that only 64% of subjects completed study treatment and follow-up. However, due
to the high morbidity associated with HSCT, discontinuations
of HSCT patients participating in clinical trials are not uncommon [32–34]. Another limitation was the lower-than-expected
incidence of confirmed CDAD, which reduced the power of the
study. From pre-study site surveys, we estimated a 20% incidence of confirmed CDAD for the placebo arm in the sample
size calculation; however, the overall incidence observed was
10.7%. This difference from our expectations was dominated
by the low incidence (8.0%) in the auto-HSCT stratum, which
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our study is 1 of a few large, randomized, double-blind, placebo-controlled studies evaluating prevention of CDAD in a
well-defined, high-risk population.
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or direct toxin (eg, ELISA) testing was allowed for confirmation
of CDAD during the treatment and follow-up periods. There
has been concern voiced over the potential for over-diagnosis of
CDAD in the context of NAAT assays, versus the opposite concern for under-diagnosis with less-sensitive ELISA-based methods [35]. At least 29/46 (63%) of CDAD cases were confirmed
using direct toxin detection. It is worth noting that the patients
in this study were diagnosed and managed for CDAD using the
standard of care at each individual site. Thus, from a resource
utilization perspective, the distinction between toxin-confirmed and gene-confirmed CDAD did not change site-specific
clinical management.
The persistent morbidity and occasional mortality associated
with CDAD among HSCT recipients warrants modalities to
prevent CDAD. Except for antimicrobial stewardship and infection control measures, few methods have consistently shown
benefits for reducing the incidence of CDAD among high-risk
patients. The necessity of chemotherapy, systemic antibiotics,
and other drugs that predispose patients to CDAD presents
challenges for the modification of risk factors in HSCT patients.
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